Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2221

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2221
---
 identify as
necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable
terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party
intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property
rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be
feasible. Even if we are able to obtain a license or sublicense, it may be nonexclusive, thereby giving our competitors access to the
same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement
technology.

Additionally,
we currently collaborate and intend to continue collaborating with academic institutions to facilitate and/or complement our preclinical
research and/or clinical development under written agreements with these institutions. In certain cases, these institutions may provide
us with an option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration. Regardless
of such options, if we are granted one, we may be unable to negotiate a license within the specified timeframe or under terms that are
acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking
our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to
maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial
condition could suffer.

The
licensing and acquisition of third-party intellectual property rights is a competitive area, and institutions, which may be more established,
or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights
that we may consider necessary or attractive in order to commercialize our product candidates. More established institutions may have
a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.
There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual
property surrounding the additional product candidates that we may seek to acquire.

Risks
Related to Intellectual Property Litigation

Third-party
claims of intellectual property infringement may prevent or delay our product discovery and development efforts.

Our
commercial success depends in part on our ability to develop, manufacture, market and